New drug aims to regrow hair in severe alopecia
NCT ID NCT06060977
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a drug called IMG-007 in 29 adults with alopecia areata who had lost at least half of their scalp hair. The main goal was to check safety, but researchers also measured hair regrowth using a standard tool. The study is now complete, and results will help decide if larger trials are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMG-007 (intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with significant hair loss from alopecia areata.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA (AA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance Clinical Research of Tampa
Tampa, Florida, 33615, United States
-
Centre de Recherche Saint-Louis
Québec, Quebec, G1W4R4, Canada
-
Dawes Fretzin Clinical Resarch Group, LLC
Indianapolis, Indiana, 47906, United States
-
Dermatology Specialists of Spokane
Spokane, Washington, 99202, United States
-
Great Lakes Research Group Inc.
Bay City, Michigan, 48706, United States
-
Guelph Dermatology Research
Guelph, Ontario, N1L0B7, Canada
-
Innovaderm Research Inc.
Montreal, Canada
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01803, United States
-
Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A.
Rogers, Arkansas, 72758, United States
-
Options Research Group
West Lafayette, Indiana, 47906, United States
-
Research Toronto
Toronto, Ontario, M2W2N4, Canada
-
SimcoMed Health Ltd.
Barrie, Ontario, L4M7G1, Canada
-
Skin Cancer and Dermatology Institute
Reno, Nevada, 89509, United States
-
Skin Health
Cobourg, Ontario, K9A0Z4, Canada
-
Skin Search of Rochester, Inc.
Rochester, New York, 14623, United States
-
Stride Clinical Research LLC
Sugar Land, Texas, 77479, United States
-
Torrance Clinical Research Institute Inc.
Lomita, California, 90717, United States